Selected Publications
View all on PubMed
Gaillard S, Oaknin A, Ray-Coquard I, Vergote I, Scambia G, Colombo N, Fernandez C, Alfaro V, Kahatt C, Nieto A, Zeaiter A, Aracil M, Vidal L, Pardo-Burdalo B, Papai Z, Kristeleit R, O'Malley DM, Benjamin I, Pautier P, Lorusso D. Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL). Gynecol Oncol. 2021 Nov; 163 (2) :237-245 . doi: 10.1016/j.ygyno.2021.08.032. Epub 2021 Sep 11. PubMed PMID: 34521554
Wethington SL, Armstrong DK, Gaillard SL. Vulnerable Older Adults With Ovarian Cancer-Time to Stop Undertreating. JAMA Oncol. 2021 Jun 1; 7 (6) :831-833 . doi: 10.1001/jamaoncol.2021.0468. PubMed PMID: 33885717
Gaillard SL, Zahurak M, Sharma A, Durham JN, Reiss KA, Sartorius-Mergenthaler S, Downs M, Anders NM, Ahuja N, Rudek MA, Azad N. A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors. Cancer. 2019 Aug 15; 125 (16) :2837-2845 . doi: 10.1002/cncr.32138. Epub 2019 Apr 23. PubMed PMID: 31012962 ; PubMed Central PMCID: PMC6663621
Gaillard SL, Andreano KJ, Gay LM, Steiner M, Jorgensen MS, Davidson BA, Havrilesky LJ, Alvarez Secord A, Valea FA, Colon-Otero G, Zajchowski DA, Chang CY, McDonnell DP, Berchuck A, Elvin JA. Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies. Gynecol Oncol. 2019 Jul; 154 (1) :199-206 . doi: 10.1016/j.ygyno.2019.04.010. Epub 2019 Apr 13. PubMed PMID: 30987772
Asaka S, Yen TT, Wang TL, Shih IM, Gaillard S. T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers. Mod Pathol. 2019 Apr; 32 (4) :576-584. doi: 10.1038/s41379-018-0172-x. Epub 2018 Nov 6. PubMed PMID: 30401949 ; PubMed Central PMCID: PMC8201475.